Afamelanotide

Mechanism

An FDA-approved implant for people with erythropoietic protoporphyria (EPP), a rare condition where sunlight causes excruciating pain. It stimulates melanin production to darken the skin, providing photoprotection. It's essentially a refined, pharmaceutical-grade version of the tanning peptides.

Effects

## Integumentary System — Photoprotective Melanogenesis [Tier 1 — FDA-Approved] Afamelanotide is a synthetic linear analog of alpha-MSH (13 amino acids) with a norleucine substitution at position 4 (replacing methionine) that confers resistance to enzymatic degradation. It is a potent, selective MC1R agonist that stimulates eumelanin production in melanocytes without UV exposure. Eumelanin (brown-black melanin) is the photoprotective form — it absorbs UV photons and neutralizes free radicals, providing a "biological sunscreen" effect. Unlike MT-2, afamelanotide has minimal activity at MC3R/MC4R/MC5R, resulting in minimal sexual side effects and reduced nausea. ## Hematologic/Metabolic — Erythropoietic Protoporphyria (EPP) [Tier 1 — FDA-Approved Indication] In EPP, patients accumulate protoporphyrin IX in erythrocytes and skin. Upon light exposure, protoporphyrin absorbs photons and generates reactive oxygen species, causing excruciating phototoxic reactions (burning, swelling, scarring). Afamelanotide increases eumelanin density in the skin, creating a UV/visible light-absorbing barrier that reduces the amount of light reaching protoporphyrin-containing dermal capillaries. Phase III trials showed EPP patients on afamelanotide could tolerate significantly more time in sunlight without pain (median increase of 69.4 hours of pain-free sun exposure over 6 months vs. placebo). ## Potential Broader Photoprotection [Tier 2 — Clinical/Preclinical Data] Afamelanotide-induced eumelanin reduces UV-induced DNA damage (cyclobutane pyrimidine dimers, CPDs) in skin biopsies. This has implications for skin cancer prevention, particularly in high-risk populations (organ transplant recipients on immunosuppressive therapy, xeroderma pigmentosum). Pilot studies in these populations have been conducted or are ongoing.

Practitioner Guide

## FDA-Approved Indication: Erythropoietic Protoporphyria (EPP) Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) received FDA approval in October 2019 for the prevention of phototoxicity in adults with EPP. It was previously approved in the EU (2014). ### Dosing (FDA-Approved Protocol) - **Formulation:** 16 mg biodegradable subcutaneous implant (about the size of a grain of rice) - **Administration:** Inserted subcutaneously above the iliac crest (hip area) by a healthcare provider using a custom applicator. No anesthesia typically required. - **Frequency:** One implant every 2 months. The implant slowly releases afamelanotide over 60+ days as the poly(DL-lactide-co-glycolide) matrix biodegrades. - **Seasonal use:** Most EPP patients use it during high-light months (spring through fall in temperate climates). Typically 3-4 implants per year. ### Clinical Observations - **Tanning:** Patients develop visible skin darkening within 2-5 days of implant insertion, peaking at 2-3 weeks. This is the eumelanin being deposited. - **Onset of photoprotection:** Most patients report increased light tolerance within 1-2 weeks. Full effect by 3-4 weeks. - **Mole darkening:** Similar to MT-2, existing nevi darken. The same melanoma screening protocol applies (baseline dermatologic exam with dermoscopy, periodic surveillance). - **Side effects:** Nausea (mild, in ~5-10% — much less than MT-2 due to MC4R selectivity), headache, injection site reaction, fatigue. Generally well-tolerated. - **Sexual side effects:** Minimal, due to low MC3R/MC4R activity. This is a key differentiator from MT-2. ### Off-Label Interest - **Vitiligo:** Afamelanotide combined with narrowband UVB has shown promising repigmentation results in pilot studies (Lim et al.). The peptide stimulates melanocyte activity in residual hair follicle melanocyte stem cells. - **Polymorphous light eruption:** Case series suggest benefit. - **Skin cancer prevention in organ transplant recipients:** Pilot studies ongoing. - **Xeroderma pigmentosum:** Small studies showing reduced UV-induced DNA damage. ### Key Differences From MT-2 | Feature | MT-2 | Afamelanotide | |---------|------|---------------| | Receptor selectivity | Non-selective (MC1R-MC5R) | MC1R selective | | Sexual side effects | Very common | Minimal | | Nausea | Common (50-85%) | Uncommon (5-10%) | | Delivery | SC injection (user-administered) | SC implant (clinician-administered) | | Regulatory status | Not approved anywhere | FDA/EMA approved for EPP | | Melanoma screening | Required | Required | | Cost | ~$20/vial (gray market) | ~$50,000+/year (specialty pharmacy) |

Dosing Protocols

Contraindications & Cautions

• hard stop — History of melanoma
  Afamelanotide is a potent MC1R agonist that stimulates melanogenesis and melanocyte proliferation. In patients with history of melanoma, stimulation of melanocyte activity carries unacceptable risk of promoting melanoma recurrence or new primary melanoma.
  Action: Do not use in patients with active melanoma or history of melanoma. Thorough skin examination required before initiation.
• hard stop — Pregnancy
  No adequate human safety data during pregnancy. Melanocortin receptor activation during pregnancy poses unknown risk to fetal development.
  Action: Do not use during pregnancy. Advise contraception during use.
• hard stop — Breastfeeding
  Insufficient data on excretion in breast milk. Melanocortin receptor activation in nursing infant poses unknown risk.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Melanocortin agonist. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Numerous atypical moles or dysplastic nevus syndrome
  Melanocyte stimulation may promote changes in existing atypical moles, potentially increasing melanoma risk in patients with dysplastic nevus syndrome.
  Action: Requires dermatologist evaluation. Full skin mapping before initiation. Regular dermatologic monitoring during use.

Evidence

• Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.

  Leaf et al. (2024) — Life (Basel) — PMID: 38929673

  In a US cohort with erythropoietic/X-linked protoporphyria, afamelanotide was associated with longer light tolerance and improved quality-of-life measures, adding real-world support to prior approval-era trial evidence.

  moderate

• Afamelanotide for Erythropoietic Protoporphyria

  Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FP, Sijbrands EJ, de Rooij FW, Lebwohl M, Naik H, Goding CR, Wilson JH, Desnick RJ (2015) — New England Journal of Medicine — PMID: 26488694

  Afamelanotide (alpha-MSH analog implant) significantly increased pain-free time in sunlight by 69.4 hours over 180 days vs placebo in patients with erythropoietic protoporphyria (EPP). The subcutaneous implant releases afamelanotide over ~60 days, stimulating eumelanin production and photoprotection. Well-tolerated with implant site discoloration and nausea as common mild effects. FDA-approved as Scenesse.

  strong

Research Summary

## Tier 1 — Strong Clinical Evidence - FDA-approved (2019) for phototoxicity prevention in EPP based on Phase III trials (PASS study, n=93): median increase of 69.4 hours pain-free sun exposure over 180 days vs. placebo - EU-approved since 2014 with extensive post-marketing safety data - Well-characterized mechanism: MC1R agonism → eumelanin synthesis → photoprotection - Selective MC1R agonist profile confirmed in binding studies ## Tier 2 — Moderate Evidence - Vitiligo: Combination with NB-UVB showed enhanced repigmentation in pilot study (Lim et al., Br J Dermatol 2015) - Demonstrated reduction in UV-induced DNA damage (CPDs) in skin biopsies after afamelanotide treatment - Pilot studies in polymorphous light eruption, solar urticaria, and actinic keratosis prevention ## Tier 3 — Preclinical/Theoretical - Skin cancer chemoprevention in immunosuppressed patients (organ transplant recipients) — clinical trials underway - Xeroderma pigmentosum photoprotection — small studies with encouraging results - Long-term melanoma risk with chronic MC1R stimulation — theoretical concern, but eumelanin is photoprotective and the net effect may be cancer-preventive. Long-term surveillance ongoing.